Section Arrow
ORKA.NASDAQ
- Oruka Therapeutics Inc
Quotes are at least 15-min delayed:2026/01/09 19:57 EST
Regular Hours
Last
 27.86
+1.46 (+5.53%)
Day High 
28.155 
Prev. Close
26.4 
1-M High
32.64 
Volume 
540.37K 
Bid
24.86
Ask
28
Day Low
26.4555 
Open
26.6 
1-M Low
25.23 
Market Cap 
1.28B 
Currency 美元 
P/E -- 
%Yield 67.21 
10-SMA 29.01 
20-SMA 29.65 
50-SMA 28.99 
52-W High 32.64 
52-W Low 5.485 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-5.88/-2.43
Enterprise Value
1.28B
Balance Sheet
Book Value Per Share
26.94
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
--
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
MREOMereo BioPharma Group plc0.4944+0.11+28.62%-- 
ASBPAspire Biopharma Holdings Inc.0.104+0.0007+0.68%-- 
RVMDRevolution Medicines118.64+11.25+10.48%-- 
ARDXArdelyx7.74+0.74+10.57%-- 
SLSSELLAS Life Sciences Group3.46-0.4-10.36%-- 
Industry overview quotes are at least 15 minutes delayed
Business Description
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.